David Tsai is a Partner in Vinson & Elkins LLP’s San Francisco office. David's practice focuses on patent, trade secret, complex breach of contract, and product defect litigation for companies innovating biotechnology (pharmaceuticals and genetic engineering), medical devices, software (Internet and mobile apps), and hardware (semiconductors, set-top boxes, smartphones, solar wafers and light-emitting diodes/LED/OLED). His legal experience includes second chairing international arbitration cases, litigating in the areas of copyrights and trademarks, preparing and prosecuting U.S. electrical engineering patent applications, drafting patentability, freedom-to-operate and non-infringement opinions, as well as patent interference in the area of biotechnology. He also represents clients in patent negotiations, licensing and overall intellectual property strategy. David has been quoted in various business and technology publications including The New York Times. He has written and lectured on Hatch-Waxman/ Abbreviated New Drug Application (ANDA) litigation, standard essential patents, FRAND/ RAND royalties, Internet software applications, stem cell gene therapy, and U.S. patent law. Prior to his legal career, David worked in product management at Internet startups focusing on developing online collaborative communications platforms. David also previously led the product management team for a real-time PCR DNA detection product line and co-developed the first online problem sets at Stanford University. David has been recognized as a top 50 California Lawyer on the Fast Track by The Recorder, Super Lawyer in Intellectual Property Litigation, and Best Lawyer Under 40 by the National Asian Pacific American Bar Association. David is fluent in spoken Taiwanese and Chinese Mandarin and represents over 30 leading Taiwan, China and Korea based companies.